Stanley Wang

2.4k total citations
28 papers, 898 citations indexed

About

Stanley Wang is a scholar working on Hepatology, Infectious Diseases and Epidemiology. According to data from OpenAlex, Stanley Wang has authored 28 papers receiving a total of 898 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Hepatology, 13 papers in Infectious Diseases and 13 papers in Epidemiology. Recurrent topics in Stanley Wang's work include Hepatitis C virus research (19 papers), HIV/AIDS drug development and treatment (10 papers) and Liver Disease Diagnosis and Treatment (6 papers). Stanley Wang is often cited by papers focused on Hepatitis C virus research (19 papers), HIV/AIDS drug development and treatment (10 papers) and Liver Disease Diagnosis and Treatment (6 papers). Stanley Wang collaborates with scholars based in United States, Canada and France. Stanley Wang's co-authors include Amy E. Wallace, William B. Weeks, Lewis E. Kazis, Austin F. Lee, Federico Mensa, Austin Lee, Shirit Einav, Edward Tam, Edward Gane and Grégory Neveu and has published in prestigious journals such as Journal of Clinical Investigation, Blood and Gastroenterology.

In The Last Decade

Stanley Wang

27 papers receiving 870 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Stanley Wang United States	13	404	367	245	128	106	28	898
Gail Thompson United States	8	193 0.5×	252 0.7×	249 1.0×	73 0.6×	64 0.6×	17	720
Gabriel García United States	23	881 2.2×	800 2.2×	249 1.0×	150 1.2×	231 2.2×	74	2.4k
Hsu‐Sung Kuo Taiwan	19	500 1.2×	863 2.4×	179 0.7×	59 0.5×	114 1.1×	28	1.4k
Nick Walsh Australia	17	541 1.3×	736 2.0×	262 1.1×	64 0.5×	102 1.0×	42	950
Vincent Nguyen United Kingdom	15	167 0.4×	264 0.7×	119 0.5×	82 0.6×	149 1.4×	54	619
Sahar Saeed Canada	19	491 1.2×	569 1.6×	346 1.4×	38 0.3×	29 0.3×	62	1.4k
Carmine Rossi United States	16	453 1.1×	487 1.3×	194 0.8×	46 0.4×	42 0.4×	85	846
Stephanie O. Klopfer United States	12	341 0.8×	535 1.5×	330 1.3×	27 0.2×	35 0.3×	33	1.3k
Edward White United States	19	147 0.4×	458 1.2×	305 1.2×	81 0.6×	245 2.3×	38	1.2k
Mandana Khalili United States	24	1.4k 3.4×	1.4k 3.8×	135 0.6×	128 1.0×	55 0.5×	125	1.8k

Countries citing papers authored by Stanley Wang

Since Specialization

Citations

This map shows the geographic impact of Stanley Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stanley Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stanley Wang more than expected).

Fields of papers citing papers by Stanley Wang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stanley Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stanley Wang. The network helps show where Stanley Wang may publish in the future.

Co-authorship network of co-authors of Stanley Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Stanley Wang. A scholar is included among the top collaborators of Stanley Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stanley Wang. Stanley Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kosloski, Matthew P., et al.. (2023). Characterizing complex and competing drug–drug interactions between the antiviral regimen of glecaprevir and pibrentasvir with rifampin or carbamazepine. Clinical and Translational Science. 16(4). 593–605. 4 indexed citations

Wagner, Brittin, et al.. (2023). Factors Influencing Admission Decisions in Skilled Nursing Facilities: Retrospective Quantitative Study. Journal of Medical Internet Research. 25. e43518–e43518. 1 indexed citations

Shebley, Mohamad, Stanley Wang, Preethi Krishnan, et al.. (2022). Phase 1 study of safety, pharmacokinetics, and antiviral activity of SARS‐CoV‐2 neutralizing monoclonal antibody ABBV‐47D11 in patients with COVID‐19. Pharmacology Research & Perspectives. 11(1). e01036–e01036. 6 indexed citations

Zhang, Jiqing, Sanjay Kumar, Muthuvel Jayachandran, et al.. (2021). Excretion of urine extracellular vesicles bearing markers of activated immune cells and calcium/phosphorus physiology differ between calcium kidney stone formers and non-stone formers. BMC Nephrology. 22(1). 204–204. 18 indexed citations

Brown, Robert S., C. Hézode, Stanley Wang, et al.. (2019). IDDF2019-ABS-0210 Preliminary efficacy and safety of 8-week glecaprevir/pibrentasvir in patients with HCV genotype 1–6 infection and compensated cirrhosis: the EXPEDITION-8 study. A146.1–A146. 8 indexed citations

Zuckerman, Eli, Julio Gutiérrez, Andrew Ustianowski, et al.. (2019). THU-198-Efficacy and safety of glecaprevir/pibrentasvir treatment for 8 weeks in treatment-naive patients with chronic hepatitis C virus infection without cirrhosis or with compensated cirrhosis: Analysis of data pooled from phase 2 and 3 studies. Journal of Hepatology. 70(1). e251–e251. 1 indexed citations

Gane, Edward, Fred Poordad, Neddie Zadeikis, et al.. (2019). Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1–6 Hepatitis C Virus Infections and Compensated Liver Disease. Clinical Infectious Diseases. 69(10). 1657–1664. 23 indexed citations

Kosloski, Matthew P., Rajneet K. Oberoi, Stanley Wang, et al.. (2019). Drug-Drug Interactions of Glecaprevir and Pibrentasvir Coadministered With Human Immunodeficiency Virus Antiretrovirals. The Journal of Infectious Diseases. 221(2). 223–231. 14 indexed citations

Puoti, Massimo, Graham R. Foster, Stanley Wang, et al.. (2018). High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1–6 patients without cirrhosis. Journal of Hepatology. 69(2). 293–300. 112 indexed citations

10.

Foster, Graham R., Gregory J. Dore, Stanley Wang, et al.. (2018). Glecaprevir/pibrentasvir in patients with chronic HCV and recent drug use: An integrated analysis of 7 phase III studies. Drug and Alcohol Dependence. 194. 487–494. 29 indexed citations

11.

Xiao, Fei, Stanley Wang, Rina Barouch‐Bentov, et al.. (2018). Interactions between the Hepatitis C Virus Nonstructural 2 Protein and Host Adaptor Proteins 1 and 4 Orchestrate Virus Release. mBio. 9(2). 30 indexed citations

12.

Gane, Edward, Fred Poordad, Joaquin Valdes, et al.. (2017). Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir in Adults with Chronic Genotype 1-6 Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis. Gastroenterology. 152(5). S1089–S1089. 1 indexed citations

13.

Puoti, Massimo, Graham R. Foster, Stanley Wang, et al.. (2017). High SVR Rates with Eight and Twelve Weeks of Pangenotypic Glecaprevir/Pibrentasvir: Integrated Efficacy Analysis of Genotype 1-6 Patients Without Cirrhosis. Gastroenterology. 152(5). S1059–S1059. 4 indexed citations

14.

Bekerman, Elena, Grégory Neveu, Ana Shulla, et al.. (2017). Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects. Journal of Clinical Investigation. 127(4). 1338–1352. 172 indexed citations

15.

Gane, Edward, Fred Poordad, Stanley Wang, et al.. (2016). High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis. Gastroenterology. 151(4). 651–659.e1. 72 indexed citations

16.

Poordad, Fred, Franco Felizarta, Stanley Wang, et al.. (2016). 752 High SVR Rates With the Combination of ABT-493 + ABT-530 for 8 Weeks in Non-Cirrhotic Patients with HCV Genotype 1 or 2 Infection. Gastroenterology. 150(4). S1046–S1047. 2 indexed citations

17.

Ng, Teresa I., Edward Tam, Rakesh Tripathi, et al.. (2016). Analysis of Hepatitis C Virus (HCV) Genotype 2 and 3 Variants in Patients Treated With Combination Therapy of Next-Generation HCV Direct-Acting Antiviral Agents ABT-493 and ABT-530. Open Forum Infectious Diseases. 3(suppl_1). 1 indexed citations

18.

Smith, Sidney C., Vera Bittner, J. Michael Gaziano, et al.. (2015). COCATS 4 Task Force 2: Training in Preventive Cardiovascular Medicine. Journal of the American College of Cardiology. 65(17). 1754–1762. 12 indexed citations

19.

Yih, W. Katherine, Ken Kleinman, Martin Kulldorff, et al.. (2009). Telephone Triage Service Data for Detection of Influenza-Like Illness. PLoS ONE. 4(4). e5260–e5260. 24 indexed citations

20.

Weeks, William B., Amy E. Wallace, Stanley Wang, Austin Lee, & Lewis E. Kazis. (2006). Rural‐Urban Disparities in Health‐Related Quality of Life Within Disease Categories of Veterans. The Journal of Rural Health. 22(3). 204–211. 109 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact